3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rhabdoid Tumor
1
Rectal Neoplasms
1
Lung Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Chordoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Advanced Solid Malignancies
1
Advanced Liver Cancers
1
Interventions
Cisplatin
14
Paclitaxel
12
pembrolizumab
9
Fluorouracil
7
Radiotherapy
6
Irinotecan
5
Esophagectomy
5
tislelizumab
4
Oxaliplatin
4
Leucovorin
4
Drug Therapy
4
Carboplatin
4
toripalimab
3
Levoleucovorin
3
Docetaxel
3
Capecitabine
3
camrelizumab
2
Taxes
2
Radiation
2
Nivolumab
2
Injections
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
sintilimab
1
palbociclib
1
nimotuzumab
1
nazartinib
1
lenvatinib
1
ivarmacitinib
1
futibatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
Tiragolumab
×
90 days
×
Clear all
NCT04543617
2026-04-17
SKYSCRAPER-07
Hoffmann-La Roche
Phase 3
Active not recruiting
760 enrolled